Syremis Therapeutics

What Syremis Therapeutics does

Syremis Therapeutics Ltd. is a clinical-stage biopharmaceutical company founded in December 2025 and headquartered in Tel Aviv, Israel with a secondary operations hub in Boston, Massachusetts. The company is developing a neuropsychiatric drug pipeline targeting major unmet needs in mental health, with two lead programs: ST-905, a dual M1/M4 preferential muscarinic agonist currently in Phase 1 development for schizophrenia and related serious psychiatric conditions; and ST-901, a next-generation NMDA receptor antagonist in IND-enabling studies for major depressive disorder and bipolar depression. Both candidates were in-licensed from Clexio Biosciences, and the company is led by co-founder and CEO Elisabeth Kogan alongside co-founder Steve Paul (former CEO and Chair of Karuna Therapeutics), with a board that includes representatives from Bain Capital Life Sciences, Third Rock Ventures, and Dexcel Pharma.

Syremis targets three large and underserved CNS indications: schizophrenia (affecting more than 20 million people worldwide), major depressive disorder, and bipolar depression. The scientific thesis is that muscarinic M1/M4 agonism can address both positive symptoms (via M4-mediated reduction of mesostriatal dopamine) and negative and cognitive symptoms (via M1 receptors in the prefrontal cortex) of schizophrenia, while next-generation NMDA antagonism could deliver a more rapid antidepressant effect than the 4–6 week onset of current standard-of-care medications. The company was launched with a $165 million Series A funding round led by Bain Capital Life Sciences, with participation from Third Rock Ventures, Dexcel Pharma, Google Ventures, Pictet, and QVT Financial.

The business model is standard clinical-stage biopharma: Syremis is pre-revenue, does not currently have commercialized products, and is not yet subject to product pricing or distribution. The capital raised in the Series A is being deployed to advance ST-905 through Phase 1 and ST-901 into IND submission, with the goal of reaching clinical proof of concept before any partnering, out-licensing, or commercialization decision. Long-term value creation is expected through either an IPO, strategic acquisition, or partnership transaction with a larger pharmaceutical company that can fund pivotal trials and commercial launch. Customer segments, in the eventual commercial sense, will be patients with schizophrenia, MDD, and bipolar depression, reached through traditional pharma sales, payer reimbursement, and physician channels following regulatory approval.

Name

Syremis Therapeutics

Legal name

Syremis Therapeutics Ltd.

Website

https://syremis.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing ST-905 (M1/M4 muscarinic agonist in Phase 1) and ST-901 (NMDA antagonist in IND-enabling studies) for schizophrenia, major depressive disorder, and bipolar depression, headquartered in Tel Aviv with a Boston operations hub.

Ownership category

akta.pro rank

Product category

Neuropsychiatric Pharmaceuticals

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

DTx/SaMD Regulatory, Quality & Compliance Software (QMS/ISO/FDA) (HLACANAN)

Keywords

• Neuropsychiatric drug development
• Muscarinic receptor agonists
• NMDA receptor antagonists
• Schizophrenia therapeutics
• Depression drug pipeline

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Marketing channels4 records

Core offering

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing two small-molecule drug candidates for serious mental health conditions. Its lead asset, ST-905, is a dual M1/M4 muscarinic agonist in Phase 1 development for schizophrenia and other serious neuropsychiatric conditions. Its second asset, ST-901, is a next-generation NMDA receptor antagonist in IND-enabling studies for major depressive disorder and bipolar depression, designed to provide a more rapid antidepressant effect than existing medications.

Product overview

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing a neuropsychiatric drug pipeline rooted in emerging and clinically validated mechanisms. The company operates two lead programs: ST-905, a dual M1/M4 muscarinic agonist in Phase 1 for schizophrenia, and ST-901, a next-generation NMDA antagonist in IND-enabling studies for major depressive disorder and bipolar depression. Both drug candidates target different neurotransmitter pathways to address significant unmet needs in mental health treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• ST-905 ST-905 is a potent M1/M4 preferential muscarinic agonist currently in Phase 1 clinical development for the treatment of schizophrenia and other serious neuropsychiatric conditions. It targets M1 and M4 receptors in brain regions linked to schizophrenia symptoms and modulates neurotransmitters including acetylcholine, dopamine, GABA, and glutamate to address positive, negative, and cognitive symptoms.
• ST-901 ST-901 is a novel NMDA receptor antagonist in IND-enabling studies, being developed for major depressive disorder and bipolar depression. It is designed to provide a more rapid antidepressant effect than most current medications, which typically take 4-6 weeks.

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Clexio BiosciencescoreTechnology or IntegrationSyremis's pipeline programs ST-905 and ST-901 originated from Clexio Biosciences, indicating an intellectual property or technology licensing relationship.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Alkermes: CNS-focused specialty biopharma with Lybalvi (schizophrenia, bipolar) and other neuropsychiatric assets. Operates directly in Syremis's lead indications with commercial-stage infrastructure.
• Intra-Cellular Therapies: Developed Caplyta (lumateperone), an approved therapy for schizophrenia and bipolar depression, and was acquired by J&J for ~$14.6B. Competes in both of Syremis's target indications.
• Acadia Pharmaceuticals: Established CNS specialty company with Nuplazid approved for Parkinson's disease psychosis; pursuing additional neuropsychiatric indications. Serves the same psychiatrist prescriber base that would prescribe ST-905/ST-901.
• Otsuka Pharmaceutical: Markets aripiprazole franchise (Abilify, Abilify Asimtufii, Rexulti) covering schizophrenia and adjunctive depression. Established incumbent in the exact indications Syremis targets.
• Sage Therapeutics: CNS-focused biopharma (now part of Biogen) that brought Zurzuvae to market for postpartum depression and has broader neuropsychiatric pipeline. Overlaps Syremis in CNS drug development capability and depression indication.
• Axsome Therapeutics: Commercial-stage CNS specialty company with Auvelity (NMDA-targeting combination) approved for major depressive disorder. Direct competitor to Syremis's ST-901 fast-onset depression program.

Direct peers

• Cerevel Therapeutics: Developed emraclidine, an M4-selective agonist for schizophrenia, before being acquired by AbbVie for ~$8.7B. Closest direct competitor to ST-905 in the muscarinic agonist space; Ray Sanchez (Syremis board) was Cerevel's former CMO.
• Karuna Therapeutics: Karuna pioneered M1/M4 muscarinic agonism in schizophrenia with xanomeline/trospium (now Cobenfy, acquired by Bristol-Myers Squibb for ~$14B). Directly comparable mechanism of action and indication focus to ST-905.
• Neumora Therapeutics: Clinical-stage neuropsychiatry company developing navacaprant (M4 antagonist) for schizophrenia alongside other CNS programs. Pursues precision psychiatry in the same symptom domains Syremis targets.

Emerging players

• MapLight Therapeutics: Clinical-stage CNS company focused on schizophrenia and other neuropsychiatric disorders using novel pharmacology including muscarinic and NMDA mechanisms. Smaller, earlier-stage competitor with overlapping pipeline.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/syremis-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syremis Therapeutics